Disease Landscape and Forecast Insights

With a drug-treated population of about 2.5 million in the United States and EU5, the moderate to severe psoriasis market has been a lucrative space for drug developers, resulting in a plethora of…

Clarivate Epidemiology’s coverage of cholangiocarcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of cholangiocarcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of cholangiocarcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of cholangiocarcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of cholangiocarcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of mucopolysaccharidoses (MPS) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States,…

Since the approval of immune checkpoint inhibitors, the treatment of bladder cancer has been transformed. Keytruda (Merck & Co.) and Opdivo (Bristol Myers Squibb) are now options in earlier…

Long-acting beta2 agonist (LABA) / long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) are gaining traction in the chronic obstructive pulmonary disease (COPD) market,…

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand whom to…

Epilepsy is a heterogeneous condition requiring individualized treatment, and a substantial number of patients are treatment-refractory. Neurologists consider many factors when selecting an…

Clarivate Epidemiology’s coverage of Fabry disease comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany…